January 12, 2022
Life Sciences
  • The federal government ordered another 600,000 doses of GlaxoSmithKline PLC and Vir Biotechnology Inc.’s monoclonal antibody treatment for COVID-19. The drugmakers plan to deliver the treatment, which is the only one thought to work against the Omicron variant, throughout the first quarter. (Article here)